Javascript must be enabled to continue!
Loss of PRMT5 promotes PDGFRα degradation during oligodendrocyte differentiation and myelination
View through CrossRef
Summary
Platelet derived growth factor receptor α (PDGFRα) signaling is required for proliferation, commitment and maintenance of oligodendrocyte (OL) precursor cells (OPCs). PDGFRα signaling promotes OPC homeostasis and its attenuation signals OPC differentiation and maturation triggering the onset of myelination of the central nervous system (CNS). The initial steps of how PDGFRα signaling is attenuated are still poorly understood. Herein we show that decreased Protein Arginine MethylTransferase5 (PRMT5) expression, as occurs during OPC differentiation, is involved in the down-regulation of PDGFRα by modulating its cell surface bioavailability leading to its degradation in a Cbldependent manner. Mechanistically, loss of arginine methylation at R554 of the PDGFRα intracellular domain reveals a masked Cbl binding site at Y555. Physiologically, depletion of PRMT5 in OPCs results in severe CNS myelination defects. We propose that decreased PRMT5 activity initiates PDGFRα degradation to promote OL differentiation. More broadly, inhibition of PRMT5 may be used therapeutically to manipulate PDGFRα bioavailability.
Title: Loss of PRMT5 promotes PDGFRα degradation during oligodendrocyte differentiation and myelination
Description:
Summary
Platelet derived growth factor receptor α (PDGFRα) signaling is required for proliferation, commitment and maintenance of oligodendrocyte (OL) precursor cells (OPCs).
PDGFRα signaling promotes OPC homeostasis and its attenuation signals OPC differentiation and maturation triggering the onset of myelination of the central nervous system (CNS).
The initial steps of how PDGFRα signaling is attenuated are still poorly understood.
Herein we show that decreased Protein Arginine MethylTransferase5 (PRMT5) expression, as occurs during OPC differentiation, is involved in the down-regulation of PDGFRα by modulating its cell surface bioavailability leading to its degradation in a Cbldependent manner.
Mechanistically, loss of arginine methylation at R554 of the PDGFRα intracellular domain reveals a masked Cbl binding site at Y555.
Physiologically, depletion of PRMT5 in OPCs results in severe CNS myelination defects.
We propose that decreased PRMT5 activity initiates PDGFRα degradation to promote OL differentiation.
More broadly, inhibition of PRMT5 may be used therapeutically to manipulate PDGFRα bioavailability.
Related Results
PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN
PRMT5 Inhibition Affects RNA Methylation and Is a Potential Therapeutic Target in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic cancer that arises from malignant transformation of plasmacytoid dendritic cell...
PF584 C‐MYC‐DRIVEN AND PRMT5‐DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE
PF584 C‐MYC‐DRIVEN AND PRMT5‐DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE
Background:The protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetrical bimethylation of arginine residues, which plays an important regulatory role in the life proce...
PDGFRα marks distinct perivascular populations with different osteogenic potential within adipose tissue
PDGFRα marks distinct perivascular populations with different osteogenic potential within adipose tissue
Abstract
The perivascular niche within adipose tissue is known to house multipotent cells, including osteoblast precursors. However, the identity of perivascular sub...
Abstract 1651: Targeting intermediates of the PRMT5/BRG1 axis as a combination therapy
Abstract 1651: Targeting intermediates of the PRMT5/BRG1 axis as a combination therapy
Abstract
Over 40% of colorectal cancer (CRC) patients harbor a mutation in the KRAS gene, leading to a worse prognosis. PRMT5 and BRG1 are proteins considered potent...
Abstract 1829: Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma
Abstract 1829: Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma
Abstract
BACKGROUND: Glioblastoma (GBM) is a highly infiltrative and aggressive malignancy with few treatment options; all patients develop recurrence after initial ...
Abstract 1725: Role of PRMT5 in neuroendocrine prostate cancer development
Abstract 1725: Role of PRMT5 in neuroendocrine prostate cancer development
Abstract
Background: Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer responsible for an estimated 20-30% of castration resistant prostat...
PRMT5 is a therapeutic target in choroidal neovascularization
PRMT5 is a therapeutic target in choroidal neovascularization
Abstract
Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients’ non-responsiveness...
Crosstalk entre la kinase LKB1 et l'arginine methyltransferase PRMT5 dans le cancer du sein
Crosstalk entre la kinase LKB1 et l'arginine methyltransferase PRMT5 dans le cancer du sein
La protéine arginine méthyltransférase 5 est la majeure arginine méthyltransférase de type II chez les mammifères, responsable de la génération de la majorité des arginines protéiq...

